文献速递肝胆胰外科

肝切除术与索拉非尼治疗晚期无转移肝细胞癌:真实世界多中心加权比较

Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.
PubMed 文献 · Ann Surg · 2022-01-01

本研究比较肝切除术(SURG)与索拉非尼(SOR)在BCLC C期无肝外转移肝细胞癌患者中的总生存(OS)和无进展生存(PFS)。采用逆概率加权平衡混杂因素后,SURG组1-3-5年OS为83.6%、68.1%、55.9%,SOR组为42.3%、17.8%、12.8%(P<0.001);PFS分别为65.9%、40.3%、24.3%和21.6%、3.5%、2.9%(P=0.007)。结论:若可行,肝切除术较索拉非尼带来更好的OS和PFS。

要点

  • BCLC C期无肝外转移但有大血管侵犯患者,肝切除术较索拉非尼显著改善OS和PFS。
  • 逆概率加权后1-3-5年OS:手术组83.6%、68.1%、55.9% vs 索拉非尼组42.3%、17.8%、12.8%。
  • 索拉非尼治疗是死亡的独立预测因素(HR 4.436;95%CI 3.19-6.15;P<0.001)。

核心结论

  • 在BCLC C期无肝外转移但有肝内门静脉侵犯的患者中,若可行,肝切除术较索拉非尼带来更好的OS和PFS。

研究设计与样本

  • 真实世界多中心加权比较研究,纳入2008-2019年478例BCLC C期无肝外转移且无主门静脉干肿瘤侵犯的患者,手术组来自HE.RC.O.LE.S.注册库(303例),索拉非尼组来自ITA.LI.CA注册库(175例),采用逆概率加权(IPW)平衡混杂因素。

主要发现

  • 逆概率加权后创建两个平衡伪人群:SURG组374例,SOR组263例。
  • 加权后1-3-5年OS:SURG组83.6%、68.1%、55.9%,SOR组42.3%、17.8%、12.8%(P<0.001)。
  • 按ECOG-PS=0和ECOG-PS>0亚组以及门静脉侵犯肝内位置亚组分析,观察到相似趋势。
  • Cox回归中,索拉非尼治疗(HR 4.436;95%CI 3.19-6.15;P<0.001)和Charlson指数(HR 1.162;95%CI 1.06-1.27;P=0.010)是死亡的仅有的独立预测因素。
  • 1-3-5年PFS:SURG组65.9%、40.3%、24.3%,SOR组21.6%、3.5%、2.9%(P=0.007)。

临床怎么用

  • 对于BCLC C期无肝外转移但存在肝内门静脉侵犯的肝细胞癌患者,若评估可行,肝切除术可能带来优于索拉非尼的生存获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. BACKGROUND DATA: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. METHODS: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. RESULTS: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). CONCLUSIONS: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Famularo S, Donadon M, Cipriani F, et al. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison. Ann Surg. 2022. PMID: 35081572. doi:10.1097/SLA.0000000000005373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。